Botanix Pharmaceuticals (BOT) H2 2025 earnings summary

Executive summary

• Achieved FDA approval and commercial launch of Sofdra, a topical gel for primary axillary hyperhidrosis, in February 2025, with rapid market uptake and strong prescription growth in the US.

• Revenue increased significantly to $5.76 million, up 857% year-over-year, driven by Sofdra sales and royalties from Japanese sublicensee.

• Net loss widened to $86.4 million, primarily due to increased operating costs for manufacturing, infrastructure, sales force expansion, and marketing to support Sofdra's launch.

• Strong cash position at year-end with $65.0 million in cash and ~$15.3 million in undrawn debt, supporting ongoing operations and growth initiatives.

Financial highlights

• Revenue from customer sales: $5.76 million (2024: $0.60 million), up 857% year-over-year.

• Net loss after tax: $86.4 million (2024: $13.9 million), reflecting a 170% increase in loss.

• Net tangible assets per share: 2.71 cents (2024: 4.38 cents).

• Cash and cash equivalents at 30 June 2025: $65.0 million (2024: $79.3 million).

• Net cash outflows from operating activities: $78.6 million (2024: $8.1 million).

Outlook and guidance

• Revenue expected to increase rapidly quarter-on-quarter due to Sofdra's growth and sales force expansion.

• No inventory purchases anticipated in 1H FY2026, with stable underlying operating costs.

• Targeting improvement in gross-to-net (GTN) yield towards 30–40% as commercialisation matures.

• Company expects to achieve profitability utilizing current cash reserves.